The global pharmaceutical company landscape is reshuffled, and three new pharmaceutical companies enter the top 20 in terms of revenue

Most of the top 20 pharmaceutical companies by revenue in 2021 will see operating income growth of more than 5%
.
Among them, the high rise reached 3836%, and the low rise was 2%
.
Among the 20 companies, Huizhi, Moderna and BioNTech also entered
.
It is reported that Huizhi will achieve total global revenue of US$17.
9 billion in 2021, which is higher than the company's guidance target of US$17.
5 billion
.
Among them, its "branded" drugs have revenue of $10.
84 billion, "specialty generics and biosimilars" have revenue of $1.
34 billion, and standard "generic drugs" have revenue of $5.
63 billion
.
In terms of market segments, Huizhi performed strongly in China and Europe
.
For the full year of 2021, sales in Greater China reached US$2.
21 billion, an increase of 2% year-on-year, and accounted for 13% of Huizhi's total global revenue
.
By integrating the strengths of the two companies in November 2020 by the merger of generic drug company Mylan and Pfizer's Upjohn divisions, Huizhi's product portfolio includes more than 1,400 approved molecules covering a broad range of key therapeutic areas
.
Moderna's 2021 global revenue is $18.
47 billion, a year-over-year increase of 2,200%
.
And BionTech's 2021 performance has achieved a 3836% increase, and its 2021 operating income will be $22.
44 billion
.
In addition to these three new companies, among these 20 companies, Johnson & Johnson performed well
.
In 2021, Johnson & Johnson achieved global revenue of $93.
78 billion
.
The three main businesses of consumer healthcare, pharmaceuticals and medical devices all contributed to its revenue growth
.
Among them, the pharmaceutical business brought in US$52 billion in revenue, a year-on-year increase of 13.
6%, mainly relying on the multiple myeloma drug daratumumab and the immunology blockbuster drug ustekinumab
.
It is reported that its ustekinumab sales will exceed $9 billion in 2021; daratumumab sales will exceed $6 billion, a year-on-year increase of 44%
.
In 2021, Pfizer will achieve total revenue of $81.
29 billion
.
But data showed its pneumococcal vaccine, Peer, fell by double digits in the fourth quarter of 2021
.
Pfizer also stated in the previous earnings call that starting in 2025, products such as Inlyta, Xeljanz, Eliquis, and Ibrance will all face the risk of patent expiration
.
But Pfizer has ample cash flow, which could help it find new business opportunities
.
Roche will generate 62.
8 billion Swiss francs ($68.
7 billion) in revenue in 2021
.
It is reported that Roche is shifting its focus to new drugs.
In 2021, Roche's drug sales increased by 3% at constant exchange rates to 45 billion Swiss francs
.
A large share of the growth came from multiple sclerosis drug Ocrevus, hemophilia drug Hemlibra, inflammatory disease treatment Actemra and PD-L1 inhibitor Tecentriq
.
AbbVie will achieve $56.
2 billion in revenue in 2021, of which Humira's sales will reach $20.
7 billion, accounting for nearly 40% of AbbVie's total revenue
.
In addition, AbbVie is also actively expanding the hematology tumor business.
In 2021, the revenue of hematology tumor products will be US$7.
228 billion, accounting for 14%
.
Novartis' total revenue in 2021 is $51.
6 billion, up 6% year-on-year, with the main growth drivers coming from anti-inflammatory biologic Cosentyx and heart drug Entresto, with sales of $4.
72 billion and $3.
55 billion, respectively
.
Merck's revenue of $48.
7 billion in 2021; BMS' revenue of $46.
4 billion in 2021; GSK's revenue of 34.
114 billion pounds ($44.
42 billion) in 2021; Sanofi's revenue of 37.
76 billion euros ($43.
12 billion) in 2021; Aspen Likang to achieve revenue of $37.
42 billion in 2021; Takeda to achieve revenue of $31.
55 billion in 2021; Eli Lilly to achieve revenue of $28.
32 billion in 2021; Bayer to achieve revenue of $28.
23 billion in 2021; Gilead to achieve $27.
3 billion in 2021 2021 revenue; Amgen revenue of $25.
98 billion in 2021; Boehringer Ingelheim revenue of $24.
36 billion in 2021; Novo Nordisk revenue of $22.
38 billion in 2021
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
window.
_bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js ?cdnversion='+~(-new Date()/36e5)]; Keywords: global pharmaceutical company pattern reshuffle, three new pharmaceutical companies enter the top 20 by revenue Institutional research, Tofflon has become the focus of attention [ Information Search ] [ Add to Favorites ] [ Tell Friends ] [ Print This Article ] [ Close Window ] Similar Information js?cdnversion='+~(-new Date()/36e5)]; Keywords: global pharmaceutical company pattern reshuffle, three new pharmaceutical companies enter the top 20 by revenue, pharmaceutical company next article: 10 pharmaceutical companies in the past week After being investigated by the agency, Tofflon became the focus of attention [ Information Search ] [ Add to Favorites ] [ Tell Friends ] [ Print This Article ] [ Close Window ] Similar Information js?cdnversion='+~(-new Date()/36e5)]; Keywords: global pharmaceutical company pattern reshuffle, three new pharmaceutical companies enter the top 20 by revenue, pharmaceutical company next article: 10 pharmaceutical companies in the past week After being investigated by the agency, Tofflon became the focus of attention [ Information Search ] [ Add to Favorites ] [ Tell Friends ] [ Print This Article ] [ Close Window ] Similar Information